RGNX

Regenxbio Inc

7.17

Oct 22 • 3:59 PM ET 0.00 (0.00%)

7.00

Aftermarket • 7:30 PM ET -0.17 (-2.37%)

Healthcare Biotechnology USA Small NASD

Peers: SLDB SRPT FDMT RARE DNLI QURE RCKT DYN TSHA OCGN

| Held by: XBI VTI IWM VXF FESM IBB IWO VTWO SCHA VHT

Scroll to Statements

Index	RUT
Market Cap	473.31M
Enterprise Value	618.03M
Income	-196.43M
Sales	174.48M
Book/sh	1.32
Cash/sh	1.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	371
IPO	Sep 17, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	2.71
P/B	5.41
P/C	4.48
P/FCF	-
EV/EBITDA	-
EV/Sales	3.54
Quick Ratio	2.86
Current Ratio	2.86
Debt/Eq	3.49
LT Debt/Eq	3.01
Option/Short	Yes / Yes

EPS (ttm)	-3.79
EPS next Y	-2.90
EPS next Q	-1.24
EPS this Y	10.54%
EPS next Y	13.81%
EPS next 5Y	26.41%
EPS past 3/5Y	16.67% -4.73%
Sales past 3/5Y	14.78% 1.97%
EPS Y/Y TTM	-9.21%
Sales Y/Y TTM	12.00%
EPS Q/Q	131.11%
Sales Q/Q	405.73%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	446.38% 10.64%

Insider Own	7.51%
Insider Trans	0.58%
Inst Own	63.73%
Inst Trans	0.43%
ROA	-40.60%
ROE	-137.63%
ROIC	-68.18%
Gross Margin	77.57%
Oper. Margin	-94.08%
Profit Margin	-112.58%
SMA20	-3.47%
SMA50	-15.51%
SMA200	-23.82%
Trades

Shs Outstand	66.01M
Shs Float	61.06M
Short Float	15.74%
Short Ratio	7.14
Short Interest	9.61M
52W High	16.19 -55.71%
52W Low	5.45 31.44%
Volatility	5.09% 6.15%
ATR (14)	0.48
RSI (14)	41.92
Beta	1.23
Rel Volume	0.84
Avg Volume	1.35M
Volume	1,132,538

Perf Week	0.14%
Perf Month	-4.40%
Perf Quarter	-26.31%
Perf Half Y	-20.24%
Perf YTD	-50.21%
Perf Year	-41.18%
Perf 3Y	-55.63%
Perf 5Y	-80.16%
Perf 10Y	-57.57%
Recom	1.50
Target Price	22.08
Prev Close	7.17
Price	7.17
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-05-26	Initiated	Mizuho	Outperform	$22
Aug-07-26	Downgrade	Barclays	Overweight → Equal Weight	$12
Jan-28-26	Resumed	Barclays	Overweight	$37
Feb-11-25	Downgrade	Goldman	Buy → Neutral	$38 → $14
Feb-07-25	Resumed	Raymond James	Outperform	$27
Nov-15-24	Resumed	Morgan Stanley	Overweight	$22
Oct-10-24	Resumed	Raymond James	Outperform	$18
Jun-07-24	Initiated	Goldman	Buy	$38
Mar-11-24	Initiated	H.C. Wainwright	Buy	$36
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$20 → $35
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$37
Feb-21-24	Resumed	Raymond James	Outperform	$45
Nov-01-23	Initiated	Stifel	Buy	$35
Jun-02-23	Initiated	Robert W. Baird	Outperform	$42
Jun-23-22	Initiated	Berenberg	Buy	$61
Dec-15-21	Initiated	Wedbush	Neutral	$29
Oct-19-21	Resumed	Morgan Stanley	Overweight	$62 → $50
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy	$60
Dec-16-20	Initiated	UBS	Buy	$57
Jun-25-20	Resumed	BofA/Merrill	Buy	$9

Show Previous Ratings

Oct-12-26 07:05AM	REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 (PR Newswire)
Oct-05-26 09:44AM	Microsoft upgraded, HubSpot downgraded: Wall Street's top analyst calls (The Fly)
07:42AM	Regenxbios Two Lead Gene Therapies Back Mizuhos Nearly 200% Upside Call (Stocktwits)
Sep-25-26 09:37AM	Regenxbio stock gains on positive gene therapy trial data (Investing.com)
Sep-24-26 07:17PM	REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting (PR Newswire)
05:30AM	Loading…
Sep-16-26 05:30AM	Trump Administration Shift Puts This Corner of Biotech Back in Favor (The Wall Street Journal)
Sep-08-26 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-26 07:05AM	REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli (PR Newswire) +10.61%
06:50AM	Regenxbios RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street (Stocktwits)
06:21AM	FDA places clinical hold on REGENXBIOs RGX-121 in MPS II trial (Hospital Management)
Aug-24-26 03:18PM	RGNX Stock On Track For Worst Day In Over Three Months BofA Says Buy Despite Disappointing FDA Hold On Gene Therapy (Stocktwits) -24.86%
10:18AM	Why Regenxbio Halted Its Gene Therapy Trial-and Why the Stock Is Tumbling (Barrons.com)
09:02AM	Why Did RGNX Stock Crash Today? (Stocktwits)
08:45AM	REGENXBIO Shares Plunge After FDA Places Clinical Hold on RGX-121 (InvestorsHub)
08:39AM	Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial (Barrons.com)
07:55AM	Loading…
07:55AM	Safety concerns spur FDA to again halt testing of Regenxbio gene therapy (BioPharma Dive)
07:05AM	REGENXBIO Announces Regulatory Update on RGX-121 for MPS II (PR Newswire)
Aug-06-26 03:02PM	Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ... (GuruFocus.com) +7.43%
07:22AM	Regenxbio: Q2 Earnings Snapshot (Associated Press)
07:05AM	REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
Aug-03-26 07:05AM	REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
Jul-18-26 02:55PM	REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting (PR Newswire)
Jul-17-26 07:00AM	REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants (PR Newswire) -11.70%
Jul-16-26 06:36PM	RGNX Stock Slumps 15% After-Hours Whats Driving The Selloff? (Stocktwits) -8.72%
04:26PM	REGENXBIO Announces Proposed Public Offering of Common Stock (PR Newswire)
Jun-29-26 07:05AM	REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone (PR Newswire) +12.88%
Jun-24-26 07:05AM	REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 (PR Newswire)
Jun-23-26 10:26AM	FDA changes rare disease tune again as it clears path for Regenxbios gene therapy (Pharmaceutical Technology) +9.70%
Jun-22-26 11:12AM	AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug \| Stock Movers (Bloomberg) +16.28%
08:44AM	RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbios Hunter Syndrome Therapy (Stocktwits)
07:39AM	Loading…
07:39AM	Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection (BioPharma Dive)
07:30AM	REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II (PR Newswire)
06:30AM	FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says (The Wall Street Journal)
May-18-26 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
May-14-26 07:03PM	Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ... (GuruFocus.com) -37.80% -8.41%
10:09AM	Regenxbio Shares Rise After Positive Duchenne Trial Results (InvestorsHub)
07:18AM	Regenxbio: Q1 Earnings Snapshot (Associated Press)
07:10AM	REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
07:00AM	REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202 (PR Newswire)
05:10AM	With new data, Regenxbio to seek FDA approval of Duchenne gene therapy (BioPharma Dive)
May-07-26 07:05AM	REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting (PR Newswire)
May-06-26 07:05AM	REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy (PR Newswire) +10.85%
Apr-01-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP (PR Newswire)
Mar-30-26 04:06AM	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
Mar-26-26 09:00AM	SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD (PR Newswire)
Mar-25-26 02:11PM	Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval (Investor's Business Daily) +8.32%
05:01AM	Mixed signals cloud the orphan drug market (Pharma Voice)
Mar-24-26 04:00PM	RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP (Business Wire) -6.35%
Mar-19-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP (PR Newswire)
Mar-17-26 04:00PM	Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP (Business Wire)
Mar-12-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST (PR Newswire)
Mar-11-26 11:45AM	REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire) -5.25%
09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP (PR Newswire)
Mar-10-26 04:00PM	RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP (Business Wire)
Mar-09-26 04:37PM	This biotech's stock soared after a 'polarizing' FDA official is stepping down (MarketWatch) +20.00%
01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga)
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
08:23AM	uniQure stock surges 36% on FDA officials departure (Investing.com)
Mar-06-26 05:56PM	FDA vaccine chief Vinay Prasad set to leave post next month (Bloomberg)
12:10AM	REGENXBIO Q4 Earnings Call Highlights (MarketBeat)
Mar-05-26 02:25PM	RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST (PR Newswire)
02:02PM	Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
08:30AM	REGENXBIO Inc. Q4 2025 Earnings Call Summary (Moby)
08:25AM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:23AM	Regenxbio: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (PR Newswire)
Mar-04-26 09:00AM	REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX (PR Newswire) +5.18%
07:05AM	REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Mar-03-26 05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal) -5.95%
Mar-02-26 05:58PM	REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses (PR Newswire)
10:00AM	Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-27-26 12:49AM	QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? (New feeds test provider finance)
Feb-26-26 04:06PM	Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug (Investor's Business Daily)
10:00AM	Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-25-26 07:05AM	REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (PR Newswire) +5.57%
Feb-20-26 04:19AM	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
Feb-17-26 07:30AM	REGENXBIO Inc. Sued for Securities Law Violations Contact the DJS Law Group to Discuss Your Rights RGNX (Business Wire)
Feb-10-26 08:51AM	FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment (Benzinga) -14.16%
06:19AM	FDA rejects Regenxbio treatment in another blow to gene therapy (BioPharma Dive)
05:49AM	REGENXBIO receives FDA response for RGX-121 application (Pharmaceutical Business Review)
Feb-09-26 04:05PM	REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II (PR Newswire)
Feb-02-26 12:18AM	Lost Money on REGENXBIO Inc. (RGNX)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile)
Jan-30-26 06:40AM	Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-26 10:10AM	Regenxbio selloff an overreaction to clinical hold, says Leerink (TipRanks) +5.36%
Jan-28-26 12:31PM	FDA Clinical Hold Knocks REGENXBIO Stock (Benzinga) -17.90%
09:22AM	The 'Confusing And Unexpected' Update That Slammed Regenxbio Stock (Investor's Business Daily)
07:30AM	REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs (PR Newswire)
06:06AM	Regenxbio gene therapy trials suspended by FDA over safety worries (BioPharma Dive)
Jan-26-26 02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
Jan-19-26 05:20PM	REGENXBIO Inc. (RGNX): A Bull Case Theory (Insider Monkey)
Jan-11-26 03:00PM	REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program (PR Newswire)
Dec-18-25 07:05AM	REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-25-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conference (PR Newswire) +9.98%
Nov-06-25 02:08PM	Regenxbio Inc (RGNX) Q3 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... (GuruFocus.com)
08:25AM	Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:25AM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
Oct-30-25 07:05AM	REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program (PR Newswire)
Oct-29-25 07:05AM	REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ciongoli Gregory Austin	Director	Aug 27 '26	Buy	9.36	53,407	499,676	118,035	Aug 27 07:03 PM
Ciongoli Gregory Austin	Director	Aug 26 '26	Buy	9.14	49,196	449,706	64,628	Aug 27 07:03 PM
PAKOLA STEVE	Chief Medical Officer	Jul 02 '26	Option Exercise	7.86	2,161	16,985	215,170	Jul 06 04:51 PM
PAKOLA STEVE	Chief Medical Officer	Jul 02 '26	Sale	13.64	2,161	29,476	213,009	Jul 06 04:51 PM
PAKOLA STEVE	Chief Medical Officer	Jul 01 '26	Option Exercise	7.86	36,725	288,658	249,734	Jul 01 08:08 PM
PAKOLA STEVE	Chief Medical Officer	Jul 01 '26	Sale	12.86	36,725	472,284	213,009	Jul 01 08:08 PM
PAKOLA STEVE	Chief Medical Officer	Jun 29 '26	Sale	11.04	19,608	216,472	213,009	Jul 01 08:08 PM
Stephen J. Pakola	Officer	Jul 01 '26	Proposed Sale	11.98	43,206	517,608		Jul 01 04:30 PM
PAKOLA STEVE	Chief Medical Officer	May 11 '26	Sale	11.02	15,309	168,705	232,617	May 13 05:18 PM
STEPHEN PAKOLA	Officer	May 11 '26	Proposed Sale	10.55	34,917	368,374		May 11 04:36 PM
PAKOLA STEVE	Chief Medical Officer	Mar 10 '26	Sale	10.35	5,124	53,033	247,926	Mar 12 06:17 PM
STEPHEN J PAKOLA	Officer	Mar 10 '26	Proposed Sale	10.38	5,124	53,187		Mar 10 04:36 PM
Mills Kenneth T.	Director	Jan 27 '26	Option Exercise	13.09	225,000	2,945,250	707,871	Jan 29 04:58 PM

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

PresidentMr. Curran M. Simpson M.S.

J.D.Mr. Patrick J. Christmas II

Executive VP & Chief Medical OfficerDr. Stephen Pakola M.D.

Executive VP & CFOMr. Mitchell Chan M.B.A.

Executive VP of Product Development & CTOMr. Craig Malzahn

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNX

Regenxbio Inc

Upgrade your Finviz experience